Related Experiment Video
Updated: Feb 18, 2026
08:26
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
12.6K
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
Jian Zhang1, Shengliang Shi, Yueling Zhang
1Department of Neurology, The Second Affiliated Hospital, Guangxi Medical University, No. 166, Daxuedong Road, Nanning, Guangxi, China, 530007.
The Cochrane Database of Systematic Reviews
|November 28, 2017
Summary
Alemtuzumab significantly reduces relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) compared to interferon beta-1a. While generally well-tolerated, careful monitoring for adverse events is crucial.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Background:
- Alemtuzumab, a monoclonal antibody, modulates the immune system by altering lymphocyte populations.
- It is recognized for its efficacy in treating relapsing-remitting multiple sclerosis (RRMS).
- This study compares alemtuzumab's effectiveness against interferon beta-1a (IFN beta-1a) in RRMS management.
Purpose of the Study:
- To evaluate and compare the efficacy of alemtuzumab versus IFN beta-1a in preventing disease activity in RRMS patients.
- To assess the tolerability and safety profiles of both treatment regimens.
Main Methods:
- A systematic review of double-blind, randomized controlled trials comparing alemtuzumab with subcutaneous IFN beta-1a was conducted.
- Three trials involving 1694 participants with RRMS were included in the analysis.
- Data on relapses, disease progression, MRI lesions, and adverse events were collected and analyzed.
Main Results:
- Alemtuzumab (12 mg/day and 24 mg/day) significantly reduced relapses and disease progression compared to IFN beta-1a.
- Significant reductions in new T2 lesions on MRI were observed with alemtuzumab.
- No statistically significant difference was found in Expanded Disability Status Scale (EDSS) changes for the 12 mg/day dose, but improvement was noted for the 24 mg/day dose.
- Adverse event rates were similar between alemtuzumab and IFN beta-1a, though specific events like infusion reactions, infections, and autoimmune events were noted with alemtuzumab.
Conclusions:
- Low- to moderate-quality evidence suggests alemtuzumab is more effective than IFN beta-1a in reducing RRMS activity over 24 to 36 months.
- Alemtuzumab is relatively well-tolerated, but requires careful monitoring for potential serious adverse effects.
- Infusion-associated reactions, infections, and autoimmune events are the most common adverse events associated with alemtuzumab.
